RARE vs. RCL
RARE (Ultragenyx Pharmaceutical Inc.) and RCL (Royal Caribbean Cruises Ltd.) are both stocks. RARE operates in Biotechnology (Healthcare), while RCL operates in Travel Services (Consumer Cyclical). Over the past 10 years, RARE returned -8.91%/yr vs 18.18%/yr for RCL. Their 0.27 correlation means their historical movements had little consistent relationship.
Performance
RARE vs. RCL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RARE achieves a 8.30% return, which is significantly lower than RCL's 15.32% return. Over the past 10 years, RARE has underperformed RCL with an annualized return of -8.91%, while RCL has yielded a comparatively higher 18.18% annualized return.
RARE
- 1D
- -4.34%
- 1M
- -25.58%
- 6M
- 3.49%
- YTD
- 8.30%
- 1Y
- -12.41%
- 3Y*
- -16.59%
- 5Y*
- -20.78%
- 10Y*
- -8.91%
- ALL TIME*
- -4.76%
RCL
- 1D
- -1.13%
- 1M
- 7.42%
- 6M
- -0.92%
- YTD
- 15.32%
- 1Y
- 3.02%
- 3Y*
- 44.96%
- 5Y*
- 33.61%
- 10Y*
- 18.18%
- ALL TIME*
- 12.85%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $49.66M | $56.10M | $61.47M | |
| $849.01M | $733.81M | $792.03M |
RARE vs. RCL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | 8.30% | -45.33% | -12.02% | 3.22% | -44.90% | -39.25% | 224.12% | -1.77% | -6.25% | -34.03% |
RCL Royal Caribbean Cruises Ltd. | 15.32% | 22.46% | 78.98% | 161.97% | -35.72% | 2.96% | -43.50% | 39.94% | -16.13% | 48.22% |
Correlation
The correlation between RARE and RCL is 0.24, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.24 |
Correlation (3Y) Balances recent behavior with more history. | 0.25 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.29 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.26 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 2014 | 0.27 |
Fundamentals
RARE:
$2.45B
RCL:
$85.37B
RARE:
-$6.09
RCL:
$16.18
RARE:
3.72
RCL:
4.63
RARE:
$669.43M
RCL:
$18.68B
RARE:
$559.44M
RCL:
$8.71B
RARE:
-$522.35M
RCL:
$7.22B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RARE vs. RCL — Risk / Return Rank
RARE
RCL
RARE vs. RCL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Royal Caribbean Cruises Ltd. (RCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RARE | RCL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.17 | ||
| Sortino ratioReturn per unit of downside risk | -0.12 | ||
| Omega ratioGain probability vs. loss probability | 1.05 | 1.05 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | -0.18 | 0.06 | -0.24 |
| Martin ratioReturn relative to average drawdown | -0.34 | 0.09 | -0.43 |
Loading charts...
Drawdowns
RARE vs. RCL - Drawdown Comparison
The maximum RARE drawdown since its inception was -89.57%, roughly equal to the maximum RCL drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for RARE and RCL.
Loading charts...
Drawdown Indicators
| RARE | RCL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.57% | -89.49% | -0.08% |
Max Drawdown (1Y)Largest decline over 1 year | -49.37% | -32.36% | -17.01% |
Max Drawdown (3Y)Largest decline over 3 years | -68.83% | -35.02% | -33.81% |
Max Drawdown (5Y)Largest decline over 5 years | -81.93% | -67.64% | -14.29% |
Max Drawdown (10Y)Largest decline over 10 years | -89.57% | -83.30% | -6.27% |
Current DrawdownCurrent decline from peak | -85.96% | -11.51% | -74.45% |
Average DrawdownAverage peak-to-trough decline | -55.11% | -27.72% | -27.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.28% | 19.89% | +6.39% |
Volatility
RARE vs. RCL - Volatility Comparison
Ultragenyx Pharmaceutical Inc. (RARE) has a higher volatility of 13.46% compared to Royal Caribbean Cruises Ltd. (RCL) at 10.87%. This indicates that RARE's price experiences larger fluctuations and is considered to be riskier than RCL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RARE | RCL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.46% | 10.87% | +2.59% |
Volatility (6M)Calculated over the trailing 6-month period | 38.75% | 33.92% | +4.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 67.17% | 47.34% | +19.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.65% | 48.37% | +6.28% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.21% | 53.36% | +1.85% |
Dividends
RARE vs. RCL - Dividend Comparison
RARE has not paid dividends to shareholders, while RCL's dividend yield for the trailing twelve months is around 1.57%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
RCL Royal Caribbean Cruises Ltd. | 1.57% | 1.25% | 0.41% | 0.00% | 0.00% | 0.00% | 1.04% | 2.22% | 2.66% | 1.81% | 2.08% | 1.33% |
Financials
RARE vs. RCL - Financials Comparison
This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Royal Caribbean Cruises Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
RARE and RCL have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RARE has higher volatility (13.46%) compared to RCL (10.87%). In terms of maximum drawdown, RARE dropped -89.57% vs RCL's -89.49%.
RCL currently has the higher Sharpe Ratio (0.04 vs -0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RARE and RCL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer